These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1840204)

  • 1. Glucose tolerance and insulin secretion in essential hypertension after treatment with an angiotensin converting enzyme inhibitor.
    Santoro D; Natali A; Galvan AQ; Masoni A; Gazzetti P; Ferrannini E
    J Hypertens Suppl; 1991 Dec; 9(6):S406-7. PubMed ID: 1840204
    [No Abstract]   [Full Text] [Related]  

  • 2. Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension.
    Sánchez RA; Traballi CA; Barclay CA; Gilbert HB; Muscará M; Giannone C; Moledo LI
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):230-4. PubMed ID: 2452319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of cilazapril and prazosin on insulin sensitivity in patients with essential hypertension].
    Cirić J; Zarković M; Trbojević B; Tasić N; Nesović M
    Med Pregl; 1995; 48(9-10):326-8. PubMed ID: 8628189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of cilazapril, a new angiotensin-converting enzyme inhibitor.
    Goldszer RC; Rodriguez R; Solomon HS
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):300S-302S. PubMed ID: 2970856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cilazapril in essential hypertension. A study of one year of continuous treatment].
    Lange H; Belz GG; Tschollar W; Wolf GK
    Med Klin (Munich); 1988 Sep; 83(17):554-8. PubMed ID: 2971866
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism.
    Shionoiri H; Sugimoto K; Minamisawa K; Ueda S; Ebina T; Matsukawa T; Gotoh E; Ishii M
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):933-8. PubMed ID: 1694916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor. Worldwide clinical experience in hypertension.
    Kögler P
    Am J Med; 1989 Dec; 87(6B):50S-55S. PubMed ID: 2532461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension.
    Ludvik B; Kueenburg E; Brunnbauer M; Schernthaner G; Prager R
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S157-9. PubMed ID: 1725031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study.
    Schneeweiss A; Marmor AT; Rettig-Stürmer G
    Cardiology; 1991; 79(1):46-8. PubMed ID: 1838032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a new angiotensin converting enzyme inhibitor, cilazapril, on circulating atrial natriuretic factor during exercise in patients with essential hypertension.
    Kohno M; Yasunari K; Murakawa K; Yokokawa K; Horio T; Kurihara N; Takeda T
    J Hypertens Suppl; 1989 Dec; 7(6):S298-9. PubMed ID: 2534417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension.
    Kobrin I; Güntzel P; Viskoper R; Paran E; Zimlichman R
    Drugs; 1991; 41 Suppl 1():31-6. PubMed ID: 1712270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilazapril: an overview of its efficacy and safety in hypertension.
    Szucs T; Schneeweiss A
    Cardiology; 1992; 80(1):34-41. PubMed ID: 1532534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to the actions of atrial natriuretic factor in insulin-dependent diabetic hypertensives and improvement with angiotensin converting enzyme inhibitor treatment.
    Fioretto P; Muollo B; Ben GP; Mollo F; Frigato F; Opocher G; Trevisan R; Carraro A; Sambataro M; Nosadini R
    J Hypertens Suppl; 1991 Dec; 9(6):S262-3. PubMed ID: 1840196
    [No Abstract]   [Full Text] [Related]  

  • 14. The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen.
    Fernandez PG; Bolli P; Lee C
    Can J Cardiol; 1990 Mar; 6(2):53-8. PubMed ID: 2138051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cilazapril, a new ACE inhibitor, in severe arterial hypertension].
    Arcila Herrera H; Montero Cervantes L; Rivero Cárdenas NA; Osorio Guerreo MI; Flores Serrano AG; González Franco MF
    Arch Inst Cardiol Mex; 1991; 61(6):573-8. PubMed ID: 1838916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New, in Austria registered specialty drugs. Inhibace (cilazapril)].
    Töglhofer W
    Wien Klin Wochenschr; 1992; 104(6):178-82. PubMed ID: 1533738
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of cilazapril therapy on glucose and lipid metabolism in patients with hypertension.
    Shionoiri H; Takasaki I; Naruse M; Nagamoti I; Himeno H; Ito T; Ohtomi S; Hata T; Shindo K; Mikami H
    Clin Ther; 1995; 17(6):1126-35. PubMed ID: 8750404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of cilazapril in hypertensive patients with moderate to severe renal impairment.
    Carlsen JE; Hansen FM; Jensen HA
    Am J Med; 1989 Dec; 87(6B):79S-82S. PubMed ID: 2532466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.
    Deget F; Brogden RN
    Drugs; 1991 May; 41(5):799-820. PubMed ID: 1712710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The acute and chronic effects of cilazapril on cardiac function in hypertensive patients.
    Schneeweiss A; Marmor A
    Kardiol Pol; 1990; 33(8):13-6. PubMed ID: 2150081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.